$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
来那度胺可明显改善多发性骨髓瘤的生存期
2025-10-19 11:44:20
Check Details
来那度胺作用机制之免疫调节作用
2025-10-19 11:44:20
Check Details
来那度胺作用机制之抗血管新生
2025-10-19 11:44:20
Check Details
来那度胺作用机制之抗肿瘤作用
2025-10-19 11:44:20
Check Details
来那度胺作用机制之骨髓瘤微环境
2025-10-19 11:44:20
Check Details
来那度胺在复发难治性多发性骨髓瘤中的应用
2025-10-19 11:44:20
Check Details
来那度胺在新诊断多发性骨髓瘤初始治疗中的应用
2025-10-19 11:44:20
Check Details
来那度胺在巩固和维持治疗中的应用
2025-10-19 11:44:20
Check Details
来那度胺的服用方法
2025-10-19 11:44:20
Check Details
来那度胺四大优点之毒性低
2025-10-19 11:44:20
Check Details
来那度胺四大优点之耐受性良好
2025-10-19 11:44:20
Check Details
来那度胺四大优点之耐药性发生较晚
2025-10-19 11:44:20
Check Details
1
2
...
912
913
914
915
916
917
918
...
4151
4152
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Adagrasib (Krazati): Full Guide to KRAS G12C Inhibitor for Cancer Treatment
2
Comprehensive Analysis of the Third-Generation EGFR-TKI
3
ATOMIC Study: Atezolizumab Plus Chemo Improves DFS in dMMR Stage III Colon Cancer
4
Oncology Immunotherapy vs Anti-Inflammatory Biologic: Dostarlimab vs Secukinumab - A Mechanism-Centered Comparison
5
Third-Generation TKI Redefining Treatment for ALK+ & ROS1+ NSCLC
6
Brigatinib Medication Case Study: Three-Year Treatment Record and Experience Sharing of ALK-Positive Lung Cancer Patient
7
What is Brigatinib (Alunbrig)? Complete Guide to ALK-Positive Lung Cancer Targeted Therapy & Medication Guidelines
8
Repotrectinib (Augtyro) Complete Medication Guide 2026: Import Original Drug Price, Eligible Patients & Full Usage Information
9
Ceritinib Capsule Storage Conditions & Expiration Guide: Room Temperature Storage, No Refrigeration Needed
10
Selumetinib for NF1 Treatment: Complete Guide to Targeted Therapy for Type 1 Neurofibromatosis
11
Alectinib for ALK-Positive Lung Cancer: Efficacy, Side Effects & Clinical Outlook
12
Which Generation TKI Is Repotrectinib? Professional Analysis of Next-Gen ROS1 Inhibitor Classification and Clinical Features